Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS3 | P17931 | 8/20 | 0.58 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.58 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.53 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12613061 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL1665970 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL416020 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL7131119 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL2989790 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL2254301 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL4314813 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL1666527 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL151041 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 | |
| SCHEMBL9350382 | 1.00 | LGALS3 (0.58) | LGALS3LGALS1LGALS9LGALS8MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100172845-A1 | COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIAL INFECTIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-07-08 | — | — | US | claimed |
| WO-2009002652-A9 | USE OF SURFACTANTS FOR TREATING MYCOBACTERIAL INFECTIONS | UNIV TEXAS (US) | 2009-02-12 | — | — | WO | claimed |
| WO-2009002652-A2 | USE OF SURFACTANTS FOR TREATING MYCOBACTERIAL INFECTIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-31 | — | — | WO | claimed |
| US-20080269163-A1 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis | UNIVERSITY OF FUKUI (JP) | 2008-10-30 | — | — | US | claimed |
| US-20100172845-A1 | COMPOSITIONS AND METHODS FOR TREATING MYCOBACTERIAL INFECTIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-07-08 | — | — | US | disclosed |
| WO-2009002652-A9 | USE OF SURFACTANTS FOR TREATING MYCOBACTERIAL INFECTIONS | UNIV TEXAS (US) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009002652-A2 | USE OF SURFACTANTS FOR TREATING MYCOBACTERIAL INFECTIONS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20080269163-A1 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis | UNIVERSITY OF FUKUI (JP) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269163-A1 | Methods and Compositions for Protecting Cells from Ultrasound-Mediated Cytolysis | GZMB, RNASE1, CASP3 | LGALS3 80/4885LGALS1 98/4885LGALS9 173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.